Michele Maio
#136,196
Most Influential Person Now
Researcher
Michele Maio's AcademicInfluence.com Rankings
Michele Maiocomputer-science Degrees
Computer Science
#6262
World Rank
#6604
Historical Rank
Machine Learning
#1972
World Rank
#1998
Historical Rank
Artificial Intelligence
#2220
World Rank
#2258
Historical Rank
Database
#3362
World Rank
#3503
Historical Rank
Download Badge
Computer Science
Michele Maio's Degrees
- Masters Artificial Intelligence University of Milan
- Bachelors Computer Engineering University of Bologna
Similar Degrees You Can Earn
Why Is Michele Maio Influential?
(Suggest an Edit or Addition)Michele Maio's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
- Nivolumab in previously untreated melanoma without BRAF mutation. (2015) (4628)
- Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (2011) (4157)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (2015) (3858)
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (2009) (2847)
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) (2731)
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) (2259)
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) (1781)
- Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. (2014) (1716)
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma (2017) (1456)
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (2018) (1224)
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. (2014) (1201)
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) (1137)
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (2013) (1136)
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. (2016) (1048)
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (2015) (978)
- High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients (2009) (803)
- Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
- Cancer classification using the Immunoscore: a worldwide task force (2012) (719)
- Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. (2013) (681)
- The role of BRAF V600 mutation in melanoma (2012) (565)
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. (2010) (484)
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) (449)
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab (2016) (442)
- Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. (2015) (416)
- Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. (2002) (387)
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. (2017) (344)
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. (2017) (328)
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. (2013) (324)
- The biology of cancer testis antigens: Putative function, regulation and therapeutic potential (2011) (287)
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. (2012) (258)
- Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels (2003) (253)
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016) (243)
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases (2009) (240)
- The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. (2010) (234)
- Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics (1985) (234)
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. (2020) (213)
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. (2016) (208)
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells (2013) (198)
- Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine (2004) (194)
- Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. (2014) (189)
- Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study (2016) (188)
- Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. (2013) (186)
- Endoglin: An accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies (2001) (185)
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. (2018) (183)
- Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. (2014) (182)
- Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. (2015) (176)
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. (2013) (174)
- Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. (2010) (170)
- Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer (2004) (169)
- Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. (2018) (163)
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (2014) (157)
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma (2021) (153)
- Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. (2000) (153)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. (2002) (149)
- Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. (2018) (148)
- Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications (2007) (148)
- Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). (2015) (137)
- Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. (2014) (132)
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. (2014) (131)
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. (2013) (128)
- A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients (2006) (128)
- Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). (1999) (128)
- Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer (2004) (127)
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme (2013) (123)
- Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. (2012) (123)
- Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma (2002) (120)
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy (2011) (120)
- Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. (2010) (119)
- Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. (1993) (115)
- Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications (2007) (113)
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study (2015) (111)
- Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. (2015) (111)
- Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases (2014) (110)
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers (2011) (108)
- Melanoma as a model tumour for immuno-oncology. (2012) (104)
- Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. (2019) (103)
- Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. (1990) (103)
- CXCR6, a Newly Defined Biomarker of Tissue-Specific Stem Cell Asymmetric Self-Renewal, Identifies More Aggressive Human Melanoma Cancer Stem Cells (2010) (100)
- Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies (2010) (98)
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (97)
- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program (2014) (96)
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (96)
- Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy (2015) (92)
- Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. (2003) (91)
- Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications (2002) (90)
- Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. (1989) (90)
- Epigenetic drugs as immunomodulators for combination therapies in solid tumors. (2014) (88)
- Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. (1996) (87)
- Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). (2016) (87)
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) (2011) (83)
- Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. (2014) (81)
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (81)
- 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? (2003) (81)
- Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. (2020) (79)
- Challenges in lung cancer therapy during the COVID-19 pandemic (2020) (78)
- Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031) (2008) (77)
- LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY (2014) (76)
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study (2022) (76)
- Epigenetic targets for immune intervention in human malignancies (2003) (75)
- Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. (2015) (74)
- Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. (2017) (74)
- Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. (2017) (73)
- Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. (2003) (71)
- Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study (2020) (69)
- Heat Shock Proteins and Their Use as Anticancer Vaccines (2004) (68)
- Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. (1991) (67)
- Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. (1989) (67)
- Implementing liquid biopsies into clinical decision making for cancer immunotherapy (2017) (66)
- Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). (2018) (66)
- Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides (2012) (65)
- Endoglin (CD105): a target for anti-angiogenetic cancer therapy. (2003) (64)
- Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients (2005) (64)
- Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. (1996) (64)
- Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. (2010) (64)
- Differential levels of soluble endoglin (CD105) in myeloid malignancies (2003) (63)
- Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status (2008) (63)
- Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. (1999) (62)
- Peptide-based vaccines for cancer therapy (2014) (60)
- MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE (1984) (60)
- Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. (2010) (57)
- Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide (2013) (57)
- Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. (2015) (57)
- 386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers (2017) (56)
- Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. (2016) (55)
- Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. (1992) (55)
- Immunotherapy of brain metastases: breaking a “dogma” (2019) (55)
- Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment. (2000) (54)
- Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. (1996) (54)
- Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients (2011) (54)
- Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy (2014) (53)
- Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients (2012) (53)
- Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models (2015) (51)
- Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications (2006) (51)
- Strong association between an HLA-DR antigen and thyroid carcinoma. (2008) (49)
- Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? (2003) (49)
- Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) (2017) (47)
- Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (47)
- Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells (2002) (47)
- Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology (2009) (46)
- A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" (2008) (46)
- Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial (2019) (45)
- Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. (2005) (45)
- Methylation‐regulated expression of HLA class I antigens in melanoma (2003) (45)
- Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients (2017) (44)
- Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). (2019) (44)
- Ocular involvement in primary hyperoxaluria. (1984) (44)
- Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. (1997) (43)
- Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. (2016) (43)
- Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). (1998) (43)
- Anti-CTLA-4 antibody adjuvant therapy in melanoma. (2010) (43)
- Biology and clinical applications of CD40 in cancer treatment. (2010) (43)
- Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. (2008) (42)
- The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma (2006) (42)
- Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (42)
- Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). (2018) (42)
- Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). (2015) (41)
- Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-alpha by the EBV-B lymphoblastoid cell line JY. (1993) (41)
- Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). (2012) (40)
- Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma (2014) (39)
- mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study (2014) (39)
- 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study (2021) (38)
- Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. (2009) (37)
- Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. (2016) (37)
- Differential modulation by tumor necrosis factor and immune interferon of HLA class‐II antigens expressed by melanoma cells (1989) (36)
- Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? (2007) (35)
- Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies (2008) (35)
- HLA and cancer: 12th International Histocompatibility Workshop study (1997) (34)
- Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma (2013) (34)
- Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response (2013) (33)
- Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. (2010) (32)
- Epigenetic remodelling of DNA in cancer. (2007) (32)
- Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era (2020) (32)
- Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab (2017) (31)
- Overexpression of protectin (CD59) down‐modulates the susceptibility of human melanoma cells to homologous complement (2000) (31)
- Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma (2021) (30)
- Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (2020) (30)
- Epigenetics meets immune checkpoints. (2015) (30)
- Update on the role of ipilimumab in melanoma and first data on new combination therapies (2013) (29)
- Expression and functional role of CD54/Intercellular Adhesion Molecule-1 (ICAM-1) on human blood cells. (1992) (29)
- Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies (2019) (28)
- The ipilimumab lesson in melanoma: achieving long-term survival. (2015) (28)
- Tumour-derived interleukin 1alpha (IL-1alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells. (1997) (28)
- Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study (2016) (27)
- Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). (2019) (27)
- Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment (2008) (27)
- coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) (2015) (26)
- A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. (2014) (26)
- NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy (2019) (25)
- Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). (2012) (25)
- CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893 (2010) (25)
- The cost of unresectable stage III or stage IV melanoma in Italy (2012) (25)
- Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability (1997) (24)
- Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome (2018) (24)
- Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma (2019) (24)
- Melanoma-associated hypopigmentation: where are the antibodies? (1996) (24)
- Corrigendum: Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. [Ann Oncol 27, (2016), (732-738)] doi:10.1093/annonc/mdw016. (2016) (24)
- Methylation‐regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications (2005) (24)
- Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (24)
- Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma (2010) (23)
- Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients (1998) (21)
- SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome (2020) (21)
- The overlooked “nonclassical” functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells (1999) (21)
- Triggering of Target of an Antiproliferative Antibody‐1 (TAPA‐1/CD81) Up‐Regulates the Release of Tumour Necrosis Factor‐α by the EBV‐B Lymphoblastoid Cell Line JY (1996) (21)
- Pregnancy and Malignant Neoplasms of the Head and Neck (1998) (21)
- Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies. (2000) (20)
- Expression and regulation of B7‐H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications (2011) (20)
- Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes (2013) (20)
- Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. (2009) (20)
- Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL) (2016) (20)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (20)
- 5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story. (2007) (20)
- Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) (2016) (20)
- CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? (2014) (20)
- Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma (2019) (20)
- Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy (2018) (19)
- Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications (2012) (19)
- Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. (2013) (19)
- Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma (2018) (19)
- Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
- Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions (1999) (19)
- Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival (2020) (19)
- Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success? (2011) (19)
- Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010" (2011) (18)
- Differential induction by immune interferon of the gene products of the HLA-D region on the melanoma cell line MeWo and its metastatic variant MeM 50-10. (1988) (18)
- Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC) (2019) (17)
- Melanoma immunotherapy: new dreams or solid hopes? (1996) (17)
- A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma (2014) (17)
- Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study (2021) (16)
- Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases (2021) (16)
- Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy (2015) (16)
- Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials (2012) (16)
- Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. (2019) (16)
- Immune checkpoint blockade in malignant mesothelioma (2014) (15)
- Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond (2012) (15)
- Epigenetics of melanoma: implications for immune-based therapies. (2013) (15)
- Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now! (2021) (15)
- Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen (1995) (13)
- Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels. (2009) (13)
- Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022). (2016) (13)
- HLA and prognostic factors in primary breast cancer (1985) (13)
- Epigenetic immunomodulation of hematopoietic malignancies. (2005) (13)
- Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024 (2012) (13)
- Melanoma and other skin tumors (2012) (13)
- Unbalanced expression of HLA‐A and ‐B antigens: A specific feature of cutaneous melanoma and other non‐hemopoietic malignancies reverted by IFN‐γ (2001) (13)
- Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238) (2017) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy. (2020) (12)
- Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone (2016) (12)
- Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (12)
- Is it the primetime for endoglin (CD105) in the clinical setting? (2006) (12)
- A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. (2011) (12)
- Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031). (2011) (12)
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma : Comparison with Regulatory T Cells and NY-ESO-1-or MelanA – Speci fi c T Cells (2014) (12)
- 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study (2015) (11)
- INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. (2017) (11)
- New dimensions in cancer biology and therapy (2000) (10)
- Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma. (2014) (10)
- Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients (2021) (10)
- Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. (1997) (10)
- Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy (2020) (10)
- Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy (2018) (10)
- A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results (2007) (10)
- Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. (2017) (10)
- Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
- Efficacy and Safety of Ipilimumab in Patients with Pretreated, Mucosal Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP) (2012) (9)
- Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: Safety analysis from the phase II NIBIT-MESO-1 study. (2017) (9)
- Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab (2020) (9)
- 1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial (2020) (9)
- Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
- Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC). (2020) (9)
- BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419). (2014) (9)
- EFFICACY AND SAFETY OF IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA WHO HAD PROGRESSED ON ONE OR MORE PRIOR THERAPIES: RESULTS FROM A SINGLE-ARM, MULTICENTER STUDY (2008) (9)
- 9312 Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs) (2009) (8)
- 9307 Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials (2009) (8)
- A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. (2015) (8)
- Epigenetic markers of prognosis in melanoma. (2014) (8)
- New horizons from immunotherapy in malignant pleural mesothelioma. (2018) (8)
- Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) (2016) (8)
- Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins. (1996) (8)
- A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL). (2013) (8)
- Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). (2015) (8)
- SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study (2021) (8)
- 9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors (2009) (7)
- Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies. (2001) (7)
- Immunosuppressive activity of T cell clones generated from human T cells stimulated with autologous TPHA cells. (1987) (7)
- In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells (1999) (7)
- Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. (2017) (7)
- Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy? (2004) (7)
- Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. (2014) (7)
- Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention (2010) (7)
- Targeting of HLA‐DR molecules transduces agonistic functional signals in cutaneous melanoma (2004) (7)
- COVID and Lung Cancer (2021) (7)
- Biphasic control of NF-kappa B activation induced by the triggering of HLA-DR antigens expressed on B cells. (1997) (6)
- Immunotherapy targeting immune check-point(s) in brain metastases. (2017) (6)
- Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial. (2012) (6)
- Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy (2018) (6)
- Recombinant transmembrane CD59 (CD59‐TM) confers complement resistance to GPI‐anchored protein defective melanoma cells * (2002) (6)
- The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma (2021) (6)
- 1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238 (2020) (6)
- CXCR 6 , a Newly Defined Biomarker of Tissue-Specific Stem Cell Asymmetric Self-Renewal , Identifies More Aggressive Human Melanoma Cancer Stem Cells (2010) (6)
- Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma. (2013) (6)
- Preparation, Characterization, and Utilization of Monoclonal Antibodies to the Gene Products of the HLA-D Region, with Special Emphasis on Those to Polymorphic Determinants (1986) (6)
- Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors (2017) (6)
- The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. (2012) (6)
- 892PTreatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP) (2017) (5)
- 9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy (2009) (5)
- Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials. (2013) (5)
- 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study (2020) (5)
- Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group. (2005) (5)
- Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients. (2011) (5)
- Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP). (2013) (5)
- B08CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL) (2015) (5)
- Cancer therapies: Basic and clinical perspectives in brain, prostate, and lung tumors: Naples, September, 24–27, 2000 * (2001) (5)
- Signaling by HLA class II antigens on B cells. (1995) (5)
- 1087OEFFICACY, SAFETY, AND QUALITY OF LIFE (QOL) DATA FROM THE EORTC 18071 PHASE III TRIAL OF IPILIMUMAB (IPI) VERSUS PLACEBO AFTER COMPLETE RESECTION OF STAGE III MELANOMA. (2014) (5)
- First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. (2018) (5)
- Expression and function of CTLA4 in melanoma. (2013) (5)
- SARS-CoV-2 vaccination and cancer therapy: a successful but mindful mix (2021) (5)
- A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions. (2014) (4)
- Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge (2018) (4)
- Myeloid-derived suppressor cells predict survival of advanced melanoma patients : comparison with regulatory T cells and NY-ESO-1-or MelanA-specific T cells (2013) (4)
- Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238) (2018) (4)
- P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients: Topic: IT Clinical (2017) (4)
- Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma (2018) (4)
- Long Term Survival and Immunological Correlates in Metastatic Melanoma Treated with Ipilimumab at 10 Mgs within an Expanded Access Program (2012) (4)
- coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) (2014) (4)
- A novel microRNA signature for the detection of melanoma by liquid biopsy (2022) (4)
- 1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC) (2020) (4)
- 795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158 (2021) (4)
- European approach to antibody-based immunotherapy of melanoma. (2002) (4)
- Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results. (2019) (4)
- The Association Between Congenital Adrenal Hyperplasia and HLA in Southern Italy (1985) (4)
- Vitiligo following melanoma in Vietnamese pot-bellied pigs: gross, ultrastructural and immunological studies (1998) (4)
- LBA39IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) (2017) (4)
- Heterogeneity in the mitogenic response of peripheral blood mononuclear cells to a pan T monoclonal antibody. (1988) (4)
- Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden (2022) (4)
- Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix (2021) (3)
- The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward (2008) (3)
- Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy (2022) (3)
- First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers (2022) (3)
- Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma (2013) (3)
- Biomarkers for immune checkpoint inhibitors--authors' reply. (2014) (3)
- Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM). (2015) (3)
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation (2021) (3)
- Adjuvant multipeptide vaccination in high-risk early melanoma patients (2008) (3)
- Abstract 680:In vivoimmunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies. (2013) (3)
- The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086) (2021) (3)
- Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology (2013) (3)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
- [Changes in immune status due to anesthesia and surgical intervention. The role of thymopentin and interleukins]. (1994) (3)
- The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level (2008) (3)
- Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP) (2013) (3)
- 12TiPA randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with melanoma with brain metastasis: The NIBIT-M2 study (2015) (3)
- Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: The NIBIT-MESO-1 study. (2016) (3)
- Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study. (2021) (3)
- Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells. (2002) (3)
- Early Access in Oncology: Why Is It Needed? (2019) (3)
- Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients. (2009) (3)
- ipilimumab Versus Placebo After Complete Resection Of Stage Iii Melanoma: Efficacy And Safety Results From The Eortc 18071 Phase Iii Trial : 374 (2014) (3)
- Is it the primetime for endoglin ( CD 105 ) in the clinical setting ? (2006) (3)
- ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. (2016) (3)
- Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts (2020) (2)
- The vitronectin receptor alpha-V beta-3, contrary to ICAM-1, is not modulated by interferon-gamma and tumour necrosis factor-alpha on melanoma cell lines. (1996) (2)
- 9318 POSTER Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma (2011) (2)
- Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel (2022) (2)
- Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ” (2012) (2)
- Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 (2017) (2)
- MA 19.02 Tremelimumab plus Durvalumab in First- or Second-Line Mesothelioma Patients: Final Analysis of the NIBIT-MESO-1 Study (2017) (2)
- Abstract CT059: Epigenetic tumor remodelling to improve the efficacy of immune checkpoint blockade: the NIBIT-M4 clinical trial (2018) (2)
- Epigenetic Mechanisms in Cancer Formation and Progression (2011) (2)
- Abstract LB-228: Pharmacokinetics of Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, in subjects with unresectable malignant mesothelioma (2014) (2)
- Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10 (2005) (2)
- 1074TiPRANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TREMELIMUMAB FOR SECOND-LINE AND THIRD-LINE TREATMENT OF UNRESECTABLE PLEURAL OR PERITONEAL MESOTHELIOMA. (2014) (2)
- The future of mesothelioma treatment: time to shift gear. (2019) (2)
- Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third joint international workshop, Lacco Ameno d'Ischia, Italy, October 2001 * (2002) (2)
- Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study (2019) (2)
- Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 (2018) (2)
- Immune checkpoint blockade in malignant mesothelioma. (2015) (2)
- The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals (2014) (2)
- Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238. (2021) (2)
- 547 Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidinecontaining demethylating dinucleotide (2010) (2)
- A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (2)
- Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features (2022) (2)
- Introduction to Immunologic Checkpoints for Cancer Treatment: From Scientific Rationale to Clinical Application (2010) (2)
- Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study (2022) (2)
- 16TiPA phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study (2015) (2)
- Targeting the immune system to tumor-associated antigens (2005) (2)
- Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. (2022) (2)
- Abstract CT270: A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/-PD-L1: The NIBIT-ML1 Study (2020) (2)
- Introduction: Cancer Epigenetics and Epigenetic Treatment of Cancer (2005) (2)
- The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086) (2022) (2)
- SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines (2022) (2)
- Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma (2013) (1)
- Cancer classification using the Immunoscore: a worldwide task force (2012) (1)
- 844 Immunomodulatory activity of epigenetic drugs combinations in mesothelioma: laying the ground for new immunotherapeutic strategies (2020) (1)
- 767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY (2008) (1)
- Epigenetically regulated tumor-associated antigens in melanoma (2009) (1)
- Abstract 2325: Immune checkpoint(s) expression in AML patients enrolled in a phase 1-2 study with guadecitabine (2016) (1)
- Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the UK, Italy, and France: results from a retrospective, longitudinal survey (MELODY) study. (2011) (1)
- Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study (2021) (1)
- Biology of Human Tumors Circulating CD 4 þ T Cells That Produce IL 4 or IL 17 When Stimulated by MelanA but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma (2014) (1)
- Immunology and cancer: gender differences (2017) (1)
- Abstract B80: A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma. (2013) (1)
- The role of BRAF V600 mutation in melanoma (2012) (1)
- QOL-07DESCRIPTION OF CLINICAL AND PATIENT REPORTED OUTCOMES ASSESSMENTS FROM A PHASE 3, MULTICENTER, RANDOMIZED TRIAL EVALUATING NIVOLUMAB MONOTHERAPY VERSUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: CHECKMATE-143. (2015) (1)
- Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients (2012) (1)
- Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). (2017) (1)
- Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC) (2021) (1)
- 19TiPA phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study (2015) (1)
- The cost of unresectable stage III or stage IV melanoma in Italy (2012) (1)
- A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007. (2020) (1)
- 9328 The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients (2009) (1)
- Nivolumab plus ipilimumab in melanoma brain metastases. (2022) (1)
- Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy (2021) (1)
- Phase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002 (2019) (1)
- Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma (2010) (1)
- Abstract CT269: A phase 2 study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007 (2020) (1)
- Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (1)
- L03.05 IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT (2013) (1)
- Immunologic checkpoints for cancer treatment: a continuing success. (2015) (1)
- Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (1)
- The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology (2018) (1)
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme (2014) (1)
- Abstract CT229: Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study (2019) (1)
- Biomolecular strategies for therapeutic intervention in cancer (2003) (1)
- Serafino Zappacosta: An Enlightened Mentor and Educator (2020) (1)
- Abstract B06: Loss of SPRY1 expression in BRAF-mutant cutaneous melanoma inhibits cell proliferation and improves response to targeted therapy (2020) (0)
- Abstract 5143: ABCG2 is involved in self renewal of melanoma cancer/initiating cells and major tumor associated antigens are expressed by ABCG2-positive cells (2010) (0)
- Melanoma cells constitutively release an anchor-positive soluble protectin (sCD59) that retains functional activities in complement-mediated cytotoxicity: 034 (1997) (0)
- T-Activation Antigens: Kinetics of Appearance and Effect on Cell Proliferation Studied with Monoclonal Antibodies (1986) (0)
- Endoglin (CD105): A Strong Candidate for Immunologic Targeting of Tumor Neovasculature in Human Malignancies (2008) (0)
- P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma (2020) (0)
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort (2014) (0)
- Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach (2019) (0)
- 997 Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study (1995) (0)
- 318 Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007 (2020) (0)
- Active immunization of melanoma patients with IL-2-OR IL-4-transduced allogeneic melanoma cells (1997) (0)
- Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts (2021) (0)
- Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008 (2009) (0)
- Immunotherapy for brain metastases and primary brain tumors. (2022) (0)
- Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer (2023) (0)
- Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program (2012) (0)
- Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012 (2013) (0)
- Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer (2012) (0)
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
- Their Interaction with Cytotoxic Cells and CD 58 / CD 2 by Human Melanoma Cells and Functional Role Differential Expression of Cell Adhesion Molecules CD 54 / CD 11 a (2006) (0)
- Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28–29 2017, Doha, Qatar) (2018) (0)
- Cell adhesion molecules (CAM) expression and functional role in cutaneous melanoma: 67 (1993) (0)
- Reviewof human cutaneous melanoma: setting the stage for new therapeutic strategies (2010) (0)
- Introduction: Melanoma: American and European perspectives on diagnosis and treatment. (2002) (0)
- “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 (2014) (0)
- 134 Epigenetic immunomodulation by SGI-110 combined with immune checkpoint blockade for new therapeutic strategies (2014) (0)
- V a c c ination o f M etastatic M elanoma P atients W ith Autologous T umor-Derived H eat S hock P rotein g p96- Peptide C omplexes: C linical a nd I mmunologic F indings (2002) (0)
- A first-line, phase II study with dacarbazine (DTIC) plus thymosin alpha 1 (Ta1) with or without interferon alpha (IFNa) vs. DTIC plus IFNa in stage IV melanoma (2006) (0)
- Abstract 2547: Peripheral immune signatures and survival in stage IV melanoma (2014) (0)
- 139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma (2021) (0)
- Differential modulation by cytokines of the gene products of the HLA-D region in melanoma cells with different metastatic potential (1989) (0)
- BRAE NRAS and p/6cDrN2'{ mutations among primary and secondary melanomas from same patients (2011) (0)
- Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009 (2010) (0)
- Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients (2011) (0)
- “Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 (2015) (0)
- OPTIMISING CANCER IMMUNOTHERAPY : CHALLENGES AND OPPORTUNITIES Summary of Presentations from a prIME Oncology Scientific Exchange on 21 st May 2016 in Amsterdam , Netherlands (2016) (0)
- 265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort (2020) (0)
- Overall Survival (OS) and New Patterns of Response in Patients (Pts) With Advanced Melanoma Treated With Ipilimumab (2008) (0)
- Down-regulated expression of HLA-B antigens in metastatic melanomas (1997) (0)
- Skip pattern approach toward the early access of innovative anticancer drugs (2021) (0)
- Immunotherapy of brain metastases: breaking a “dogma” (2019) (0)
- Prognostic relevance of baseline neutrophils and derived neutrophil to lymphocyte ratio for ipilimumab-treated advanced melanoma patients. (2015) (0)
- 1109PVEMURAFENIB IN BRAFV600 MUTATED METASTATIC MELANOMA (MM): A SUBANALYSIS OF THE ITALIAN POPULATION OF A GLOBAL SAFETY STUDY. (2014) (0)
- First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results. (2022) (0)
- New mechanism of escape from immunosurveillance of thyroid carcinoma cells: involvement of PKC pathway. (1995) (0)
- 468 Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma (2012) (0)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (0)
- Abstracts reprinted from journal of clinical oncology (2007) (0)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
- MA05.07 Efficacy and Safety of Re-Treatment with Tremelimumab and Durvalumab Within the NIBIT-MESO-1 Study (2019) (0)
- Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study. (2019) (0)
- Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study (2013) (0)
- Abstract 4488: Immunomodulatory activity of epigenetic drugs: Laying the ground for new combined immunotherapeutic strategies for glioblastoma (2020) (0)
- Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI) (2020) (0)
- Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID (2023) (0)
- “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 (2016) (0)
- Perspectives of Immunotherapy in Advanced Melanoma: Combinations and Sequencing (2021) (0)
- Abstract 4806: Spry1 as a potential new hypoxia modulator in cutaneous melanoma (2023) (0)
- First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817 (2023) (0)
- The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates (2021) (0)
- 12P Multi-omics correlation with clinical outcome in metastatic melanoma patients treated with ipilimumab plus guadecitabine: The NIBIT-M4 study (2022) (0)
- From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma (2023) (0)
- Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor (2022) (0)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (0)
- Endoglin is expressed on human osteoclast progenitor cell (FLG 29.1) (1995) (0)
- Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells (2023) (0)
- Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop” (2022) (0)
- Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors (2014) (0)
- Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2018) (0)
- 9327 Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients (2009) (0)
- Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010 (2011) (0)
- Experimental and Clinical Immunology (1998) (0)
- Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203). (2021) (0)
- PCN111 HEALTH-CARE RESOURCE UTILIZATION IN ADVANCED MELANOMA: AN ANALYSIS FROM THE MELODY OBSERVATIONAL STUDY (2010) (0)
- Abstract A256: Epigenetic priming with novel hypomethylating agent SGI-110 improved antitumor activity of CTLA-4 blockade in a syngenic mouse model. (2013) (0)
- A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (0)
- Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment (2013) (0)
- OR.19. Can Epigenetics Have a Clinical Impact in the Treatment of Melanoma (2006) (0)
- Letters to the Editor (1996) (0)
- Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer (2021) (0)
- Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial (2023) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Epigenetically‐Regulated Therapeutic Tumor‐Associated Antigens (2009) (0)
- Abstract 3273: Guadecitabine plus ipilimumab in unresectable melanoma: Five-year follow-up and correlation with integrated, multi-omic analysis in the NIBIT-M4 trial (2023) (0)
- Review Epigenetic remodelling of DNA in cancer (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michele Maio?
Michele Maio is affiliated with the following schools:
